Castle Biosciences Expands Evidence Supporting the Performance of its TissueCypher® Barrett’s Esophagus Test in Predicting Future Development of Esophageal Cancer Through Multiple Data Presentations at DDW 2024
2024年5月14日 - 8:00PM
ビジネスワイヤ(英語)
In collaboration with leading GI experts,
Castle has also planned several educational sessions at DDW 2024,
including a product theater and two American Society for
Gastrointestinal Endoscopy (ASGE) theater talks
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving
health through innovative tests that guide patient care, will share
three abstracts supporting the ability of its TissueCypher® test to
predict risk of progression to esophageal cancer in patients with
Barrett’s esophagus (BE) at the Digestive Disease Week (DDW) 2024
Annual Meeting, being held May 18-21, 2024, in Washington, D.C.
“We are committed to advancing care for patients with BE in an
effort to reduce the incidence of esophageal cancer and
importantly, to help save patients’ lives by informing earlier,
potentially life-saving interventions,” said Robert Cook, Ph.D.,
senior vice president of research and development at Castle
Biosciences. “The data we are sharing at DDW 2024 in collaboration
with renowned GI experts from the U.S. and abroad further expand
the substantial clinical evidence supporting our TissueCypher test
and its ability to improve the care that BE patients receive.”
The following abstracts will be presented at DDW 2024 (all times
Eastern Time). Abstracts will be available on the DDW ePosters site
and to conference attendees in the DDW meeting planner and mobile
app after 12:01 a.m. on Sunday, May 19, 2024.
- Podium presentation title: The Tissue Systems Pathology Test
Enables Risk-Aligned Management for Patients with Barrett’s
Esophagus Presenter and Lead Author: Lucas Duits, M.D., Ph.D.,
Amsterdam University Medical Centers Abstract #: 392 Session Type:
Research Forum Session #: 3265 Session Title: Advances in Barrett's
Esophagus Date & Time: Sunday, May 19, 11:15-11:30 a.m.
- Title: The Tissue Systems Pathology Test Predicts Risk of
Malignant Progression in Patients with Barrett's Esophagus: A
Systematic Review and Meta-Analysis Presenter and Lead Author:
Ashley Tran, M.D., Keck School of Medicine, University of Southern
California (USC) Abstract #: Su1266 Session Type: Poster Session
Session #: 7110 Session Title: Barrett's Esophagus and
Esophagogastric Junction Neoplasia - Epidemiology, Risk factors,
Screening, Surveillance, Treatment and Outcomes Session Date &
Time: Sunday, May 19, 12:30-1:30 p.m.
- Title: The Tissue Systems Pathology Test Provides Clinically
Actionable Risk-Stratification in Patients with Barrett’s
Esophagus: A Multicenter U.S. Clinical Experience Presenter and
Lead Author: Harshit Khara, M.D. FACG, FASGE, Geisinger Health
System Abstract #: Su1267 Session Type: Poster Session Session #:
7110 Session Title: Barrett's Esophagus and Esophagogastric
Junction Neoplasia - Epidemiology, Risk factors, Screening,
Surveillance, Treatment and Outcomes Session Date & Time:
Sunday, May 19, 12:30-1:30 p.m.
Visit Castle at DDW 2024
For more information on the above abstracts and the TissueCypher
test, visit Castle at booth 3737; a complete list of Castle’s
activities at DDW 2024 can be found at
https://info.castlebiosciences.com/ddw2024. Key events include the
following:
Product Theater
- BEyond the diagnosis: personalized, precision medicine in the
management of Barrett’s esophagus Panel discussion to include:
Emmanuel Gorospe, M.D., MPH, FACP, FACG, FASGE, GI medical director
at Castle Biosciences; Dan Lister, M.D., FACS, FAFS, surgeon and
director of the Arkansas Heartburn Treatment Center, and co-founder
and president elect of the American Foregut Society; Dr. Farhan
Quader, M.D., interventional gastroenterologist at NorthShore
University Hospital in Chicago; Sarah Enslin, PA-C, Division of
Gastroenterology and Hepatology at the University of Rochester
Medical Center Rochester in New York Location: DDW Product Theater
1 Date & Time: Tuesday, May 21, 12-12:45 p.m.
ASGE Theater Talks
- A modern approach to the clinical management of patients with
Barrett’s esophagus Presenter: Harshit Khara, M.D., FACG, FASGE,
Geisinger Medical Center Date & Time: Saturday, May 18,
10:15-10:45 a.m.
- Leveraging clinically impactful risk stratification for
patients with Barrett’s esophagus Presenter: John C. Lipham, M.D.,
Keck Medicine of USC Date & Time: Monday, May 20, 2:45-3:15
p.m.
Additionally, Castle is collaborating with several
organizations, including the ASGE, Esophageal Cancer Action
Network, American Muslim Gastroenterologist Network, American
Foregut Society and Women in Endoscopy on various educational and
networking events taking place throughout the meeting.
About Digestive Disease Week® (DDW)
Digestive Disease Week® (DDW) is the largest international
gathering of physicians, researchers and academics in the fields of
gastroenterology, hepatology, endoscopy and gastrointestinal
surgery. Jointly sponsored by the American Association for the
Study of Liver Diseases (AASLD), the American Gastroenterological
Association (AGA), the American Society for Gastrointestinal
Endoscopy (ASGE) and the Society for Surgery of the Alimentary
Tract (SSAT), DDW is an in-person and online meeting from May
18-21, 2024. The meeting showcases more than 4,400 abstracts and
hundreds of lectures on the latest advances in GI research,
medicine and technology. More information can be found at
www.ddw.org.
About TissueCypher® Barrett’s Esophagus Test
The TissueCypher Barrett’s Esophagus test is Castle’s precision
medicine test designed to predict future development of high-grade
dysplasia (HGD) and/or esophageal cancer in patients with Barrett’s
esophagus (BE). The TissueCypher Barrett’s Esophagus test is
indicated for use in patients with endoscopic biopsy confirmed BE
that is graded non-dysplastic (NDBE), indefinite for dysplasia
(IND) or low-grade dysplasia (LGD); its clinical performance has
been supported by 13 peer-reviewed publications of BE progressor
patients with leading clinical centers around the world. The test
received Advanced Diagnostic Laboratory Test (ADLT) status from the
Centers for Medicare & Medicaid Services (CMS) in March
2022.
About Castle Biosciences
Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics
company improving health through innovative tests that guide
patient care. The Company aims to transform disease management by
keeping people first: patients, clinicians, employees and
investors.
Castle’s current portfolio consists of tests for skin cancers,
Barrett’s esophagus, mental health conditions and uveal melanoma.
Additionally, the Company has active research and development
programs for tests in other diseases with high clinical need,
including its test in development to help guide systemic therapy
selection for patients with moderate-to-severe atopic dermatitis,
psoriasis and related conditions. To learn more, please visit
www.CastleBiosciences.com and connect with us on LinkedIn,
Facebook, X and Instagram.
DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-SCC, MyPath
Melanoma, DiffDx-Melanoma, TissueCypher, IDgenetix, DecisionDx-UM,
DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of Castle
Biosciences, Inc.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended, which are subject to the “safe harbor” created by those
sections. These forward-looking statements include, but are not
limited to, statements concerning: (i) Castle’s ability to advance
care for patients with BE; and (ii) the ability of the TissueCypher
test to predict the risk of progression to esophageal cancer in
patients with BE and to help save patients’ lives by informing
earlier, potentially life-saving interventions. The words “can,”
“would” and similar expressions are intended to identify
forward-looking statements, although not all forward-looking
statements contain these identifying words. We may not actually
achieve the plans, intentions or expectations disclosed in our
forward-looking statements, and you should not place undue reliance
on our forward-looking statements. Actual results or events could
differ materially from the plans, intentions and expectations
disclosed in the forward-looking statements that we make. These
forward-looking statements involve risks and uncertainties that
could cause our actual results to differ materially from those in
the forward-looking statements, including, without limitation:
subsequent study or trial results and findings may contradict
earlier study or trial results and findings or may not support the
results shown in this study, including with respect to the
discussion of TissueCypher in this press release; actual
application of our TissueCypher test may not provide the
aforementioned benefits to patients; and the risks set forth under
the heading “Risk Factors” in our Annual Report on Form 10-K for
the year ended December 31, 2023, our Quarterly Report on Form 10-Q
for the quarter ended March 31, 2024 and in our other filings with
the SEC. The forward-looking statements are applicable only as of
the date on which they are made, and we do not assume any
obligation to update any forward-looking statements, except as may
be required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240514602230/en/
Investor Contact: Camilla Zuckero
czuckero@castlebiosciences.com
Media Contact: Allison Marshall
amarshall@castlebiosciences.com
Castle Biosciences (NASDAQ:CSTL)
過去 株価チャート
から 5 2024 まで 6 2024
Castle Biosciences (NASDAQ:CSTL)
過去 株価チャート
から 6 2023 まで 6 2024